InsiderTrades.com logo
Crispina Calsada net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Crispina Calsada Biography and Net Worth

CFO of Regulus Therapeutics

Cris joined Regulus in August 2019 and currently serves as chief financial officer. She joined Regulus from Sanifit where she served as chief financial officer. Before joining with Sanifit, Cris spent several years as a finance consultant to life sciences companies. From 2004 until 2015, she served in positions of increasing responsibility with Ambrx, culminating as chief operating officer and vice president of finance and guiding the company through its acquisition. Prior to Ambrx, she worked for Sony Online Entertainment as executive director of finance and controller. Earlier in her career, she practiced as a certified public accountant. Cris received a B.S. in business administration with an emphasis in accounting from San Diego State University and an MBA from the University of Southern California Marshall School of Business.

What is Crispina Calsada's net worth?

The estimated net worth of Crispina Calsada is at least $412.62 thousand as of January 13th, 2025. Ms. Calsada owns 50,566 shares of Regulus Therapeutics stock worth more than $412,619 as of December 4th. This net worth evaluation does not reflect any other assets that Ms. Calsada may own. Additionally, Ms. Calsada receives an annual salary of $579,300.00 as CFO at Regulus Therapeutics. Learn More about Crispina Calsada's net worth.

How old is Crispina Calsada?

Ms. Calsada is currently 54 years old. There are 4 older executives and no younger executives at Regulus Therapeutics. The oldest executive at Regulus Therapeutics is Mr. Christopher Ray Aker J.D., Senior VP, General Counsel & Corporate Secretary, who is 63 years old. Learn More on Crispina Calsada's age.

What is Crispina Calsada's salary?

As the CFO of Regulus Therapeutics Inc., Ms. Calsada earns $579,300.00 per year. The highest earning executive at Regulus Therapeutics is Mr. Joseph P. Hagan M.B.A., CEO & Director, who commands a salary of $958,230.00 per year. Learn More on Crispina Calsada's salary.

How do I contact Crispina Calsada?

The corporate mailing address for Ms. Calsada and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Crispina Calsada's contact information.

Has Crispina Calsada been buying or selling shares of Regulus Therapeutics?

Crispina Calsada has not been actively trading shares of Regulus Therapeutics in the last ninety days. Most recently, Crispina Calsada sold 38,716 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a transaction totalling $48,782.16. Following the completion of the sale, the chief financial officer now directly owns 50,566 shares of the company's stock, valued at $63,713.16. Learn More on Crispina Calsada's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), David Baltimore (Director), Crispina Calsada (CFO), Kathryn Collier (Director), Denis Drygin (Insider), Joseph Hagan (CEO), and Preston Klassen (Insider). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, Regulus Therapeutics insiders bought shares 3 times. They purchased a total of 81,610 shares worth more than $171,166.60. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 223,998 shares worth more than $282,237.48. The most recent insider tranaction occured on June, 3rd when insider Preston Klassen bought 12,000 shares worth more than $95,880.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 6/3/2025.

Crispina Calsada Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2025Sell38,716$1.26$48,782.1650,566View SEC Filing Icon  
1/18/2024Sell5,468$1.19$6,506.925,782View SEC Filing Icon  
See Full Table

Crispina Calsada Buying and Selling Activity at Regulus Therapeutics

This chart shows Crispina Calsada's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.16
Low: $8.16
High: $8.16

50 Day Range

MA: $8.10
Low: $7.87
High: $8.30

2 Week Range

Now: $8.16
Low: $0.83
High: $8.35

Volume

N/A

Average Volume

1,018,158 shs

Market Capitalization

$564.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35